Nevro Corp. (NYSE:NVRO) Shares Purchased by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky lifted its stake in shares of Nevro Corp. (NYSE:NVROGet Rating) by 52.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 28,156 shares of the medical equipment provider’s stock after purchasing an additional 9,674 shares during the quarter. Teachers Retirement System of The State of Kentucky owned about 0.08% of Nevro worth $2,036,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. CWM LLC raised its position in shares of Nevro by 29.6% during the 1st quarter. CWM LLC now owns 757 shares of the medical equipment provider’s stock worth $55,000 after purchasing an additional 173 shares during the period. FourThought Financial LLC raised its position in shares of Nevro by 49.1% during the 1st quarter. FourThought Financial LLC now owns 683 shares of the medical equipment provider’s stock worth $49,000 after purchasing an additional 225 shares during the period. Eaton Vance Management raised its position in shares of Nevro by 1.2% during the 4th quarter. Eaton Vance Management now owns 24,841 shares of the medical equipment provider’s stock worth $1,989,000 after purchasing an additional 304 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Nevro by 104.4% during the 1st quarter. Nisa Investment Advisors LLC now owns 920 shares of the medical equipment provider’s stock worth $67,000 after purchasing an additional 470 shares during the period. Finally, Teacher Retirement System of Texas raised its position in shares of Nevro by 8.3% during the 1st quarter. Teacher Retirement System of Texas now owns 6,825 shares of the medical equipment provider’s stock worth $494,000 after purchasing an additional 523 shares during the period. 96.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently weighed in on NVRO. Wells Fargo & Company dropped their price target on Nevro from $90.00 to $86.00 and set an “overweight” rating on the stock in a research report on Thursday, August 4th. Truist Financial decreased their price objective on Nevro to $45.00 in a report on Friday, July 22nd. StockNews.com raised Nevro from a “sell” rating to a “hold” rating in a report on Thursday, July 21st. Morgan Stanley decreased their price objective on Nevro from $55.00 to $54.00 and set an “equal weight” rating for the company in a report on Thursday, August 4th. Finally, JMP Securities decreased their price objective on Nevro from $125.00 to $95.00 and set a “market outperform” rating for the company in a report on Thursday, May 26th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $71.10.

Nevro Stock Performance

NVRO opened at $46.94 on Wednesday. The firm has a market cap of $1.66 billion, a PE ratio of -11.76 and a beta of 0.93. The company has a quick ratio of 5.36, a current ratio of 6.65 and a debt-to-equity ratio of 0.81. The business has a fifty day simple moving average of $46.41 and a 200-day simple moving average of $53.23. Nevro Corp. has a fifty-two week low of $39.41 and a fifty-two week high of $126.61.

Nevro (NYSE:NVROGet Rating) last released its quarterly earnings data on Wednesday, August 3rd. The medical equipment provider reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.10. The business had revenue of $104.21 million during the quarter, compared to analyst estimates of $104.66 million. Nevro had a negative return on equity of 43.73% and a negative net margin of 35.96%. As a group, equities analysts predict that Nevro Corp. will post -2.9 EPS for the current fiscal year.

About Nevro

(Get Rating)

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems.

Read More

Institutional Ownership by Quarter for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.